fbpx

Science

The anti-viral formulation of APT™ T3X the SARS-CoV-2 virus, NL-63 Coronavirus and Influenza virus proving to be a highly effective method of protection against Coronavirus (COVID-19) infectivity when used appropriately.

APT™ T3X provides another layer of protection to the individual to decrease the viral load of exposure.

Highly effective protection against COVID-19

With the current environment, there is a global race to develop a trusted and safe therapeutic treatment against COVID-19. APT™ T3X is a tetracycline hydrochloride first aid antibiotic produced by APT, LLC. It is an over-the-counter, FDA-registered formulation that is proven to abolish viral infectivity.1

IT IS ALL ABOUT THE NOSE
PREVENTION SHOULD FOCUS ON INTRANASAL PROTECTION

These recent articles from MIT Research and John Hopkins Research support the approach to providing an effective anti-viral barrier within the nose to decrease the viral load of exposure.2 3

“Researchers at MIT; the Ragon Institute of MGH, MIT, and Harvard; and the Broad Institute of MIT and Harvard; along with colleagues from around the world have identified specific types of cells that appear to be targets of the coronavirus that is causing the Covid-19 pandemic. In the nasal passages, the researchers found that goblet secretory cells, which produce mucus, express RNAs for both of the proteins that SARS-CoV-2 uses to infect cells.” 2

John Hopkins Medicine reported that the “hook” of cells used by SARS-CoV-2 to latch onto and infect cells is up to 700 times more prevalent in the olfactory supporting cells lining the inside of the upper part of the nose than in the lining of the rest of the nose and windpipe that leads to the lungs. These are the supporting cells necessary for the function/development of odor-sensing cells.

“Understanding of the pattern of viral load in tissues of COVID-19 patients is critical for diagnosis, management of transmission, and potential treatment strategies. Detection of SARS-CoV-2 in clinical specimens shows that the highest viral copy number is found in nasal swabs (~200 fold), compared to bronchoalveolar lavage or pharyngeal swabs. In the early stages of SARS-CoV-2 infection, viral RNA can readily be detected in upper respiratory specimens but not in blood, urine, or stool. These findings, taken together with ACE2 protein cellular localization presented here, suggests that active virus infection and replication occurs in the apical layer of nasal and olfactory mucosa. The differential expression of ACE2 in the olfactory neuroepithelium and respiratory epithelium may help account for the spectrum of nasal-related symptoms, while also raising the intriguing possibility that COVID-19 may be amenable to novel therapeutic approaches. Consideration should be given to the delivery of topical anti-viral additives, such as detergent or povidone-iodine, directed at the nasal and nasopharyngeal viral reservoirs.” 3

HOW IT WORKS

The Advanced Performance Technology™ combined with Tetracycline, imparts a biophysical and biochemical neutralization effect on viruses. The mechanical nature of disrupting the lipid envelope of the Coronavirus immediately neutralizes the virus. This neutralization inactivates the ability of the virus to penetrate into the cells of the body and begin replication.

APT™ T3X is applied to the nasal passages (inside of the nose) and immediately acts to reduce the viral load (the number of viral particles present) of exposure to the SARS-CoV-2 virus. Viral load is directly connected to disease severity. This revolutionary and proprietary topical formulation is empowered by the Advanced Performance Technology™ platform, destroying viruses before they can infect and cause disease.

The APT™ T3X has NO documented side effects in over 8 years of application and use. Its ability to disrupt, destroy, and neutralize viruses is unmatched. When used appropriately, this is a powerful step in the prevention of COVID-19.

While vaccines are currently available, the evidence of growing viral variant resistance is around us. The current challenges with viral mutations (already documented with SARS-CoV-2) will impact any efficacy of vaccines over time. Vaccine use is important, and now applying the APTT3X™ as an added layer of protection will help protect the "carrier state" of these viral variants.

The one key step for the general population, that until now has been missing, is the direct application of a barrier to decrease the Viral Load of Exposure.

APT™ T3X PROVIDES ANOTHER BARRIER OF PROTECTION AGAINST THE COVID-19 VIRUS.

CLINICAL TRIAL RESULTS DEMONSTRATE A 150% DECREASE in Risk of Contracting SARS-CoV-2 (COVID)

"APTT3X™ is a self-administered process of swabbing the lower passages of the nose, represents a scalable preventative solution that could slow the spread of COVID-19 on a global scale"
— Dr. Ernesto Cesar Pinto Leal Junior, ELJ Consultancy

Conducted under the direction or of Dr. Ernesto Leal, sponsored by the Nove de Julho University, Sao Paulo at the Santa Casa de Misericórdia de Porto Alegre Hospital, a randomized, triple blinded clinical trial was performed in Brazil, in the state of Rio Grande de Sul. Rio Grande de Sul is dealing with the highest level of COVID-19 infectivity, hospitalizations and deaths in the country. The entirety of the trial took place under BLACK FLAG warnings from the Brazilian public health system.

Multiple variants of SARS-CoV-2 were present across this geographic region where the trial took place. The trial results demonstrated there was a DECREASED infection risk of 150% for individuals when using a single, daily application of the intranasal APTT3X™ formulation.

Link for Clinical Trial Results:

https://clinicaltrials.gov/ct2/show/results/NCT04716426?term=ernesto+leal&draw=1&view=results

EFFICACY STUDY

Virology Research Services, Ltd., evaluated the in vitro anti-viral efficacy of the APT™ T3X formulation against the SARS-CoV-2 (cause of COVID-19), Coronavirus (NL63) and Influenza virus proving—through a variety of testing protocols—that when appropriately used, APT™ T3X is a highly effective preventative against the Coronavirus, thus an effective step to decrease the viral load of exposure.

Chart showing No infectious virus was detected after 30 seconds of T3X treatment

Figure 1. Decreased infectivity of virus that has been in contact with T3X compared with phosphate buffer saline (PBS). No infectious virus was detected after 30 seconds of T3X treatment. The experiment was performed in technical triplicates.

Dr. Michela Mazzon, lead scientist at Virology Research Services, found that “the APT™ T3X formulation abolishes viral infectivity in vitro.”

WHAT DOCTORS ARE SAYING

Dr. Gregory D. Hobbs, Past Chair, Department of Emergency Medicine at Texas A&M College of Medicine had this to say about the APT™ T3X formulation:

“I have recently been introduced to a novel topical medication delivery formulation, APT™ T3X, which appears to provide a significant protective barrier to help prevent the user from contracting COVID-19. This formulation has been in use since 2012 for topical delivery of antibiotics in wound care and acne treatment, and there have been no reported side-effects from its use in these patients.

APT™ T3X recently underwent testing at an accredited virology research lab in England to determine its ability to kill both Corona and influenza viruses. The results showed that APT™ T3X killed at least 99.9% of these viruses. Research has shown that COVID-19 is primarily contracted by humans through the nose. Twice daily nasal application of APT™ T3X therefore appears to have the ability to provide an additional layer of protection against COVID-19, with no known side-effects.

In normal times, I would recommend that this product undergo a randomized, controlled clinical trial before wide-spread clinical adoption. However, these are not normal times, and traditional scientific practices have been suspended in favor of expedited processes for adoption of low risk, potentially helpful medications. Within this context, I strongly recommend making this product immediately available to frontline medical providers, schoolteachers and other essential workers as an additional layer of protection, in combination with the current CDC guidelines for mask wearing and social distancing.

There is no downside to this approach, and potentially a very significant upside for our at-risk populations. I will certainly be using APT™ T3X during my emergency department shifts.”

As a physician caring for patients throughout the entirety of the pandemic, I have been using APTT3X daily. For over a year, and prior to being vaccinated, I have personally been using intranasal APTT3X formulation as part of my COVID-19 preventative strategy. Though I am now vaccinated, I continue to use l APTT3X daily to protect against COVID and any new variants.

Dr. Daniela Vincent, D.O.

Capt, USAF

As a physician on the front lines, I have been personally using the APTT3X formulation intranasal daily for over a year as my COVID preventative strategy, before the routine availability of vaccines. I have since been vaccinated for COVID 19 and I continue to use the APTT3X daily to protect against the new variants.

Dr Anthony Gross, DO MSc,

Medical Director & Director of Occupational HealthSanta Cruz Valley Regional Hospital, Tucson AZ

The APT™ T3X is an additional layer of protection, not a stand-alone solution. Following the CDC guidelines for COVID-19 prevention is always recommended.

ADDITIONAL RESOURCES

Virology Studies:

https://aptt3x.com/wp-content/themes/twentynineteen-child/pdf/PTFH-SARS-CoV2-Study-Report.pdf

https://www.aptdeliverysystem.com/wp-content/uploads/PTFH-NL63-Study-Report.pdf

https://www.aptdeliverysystem .com/wp-content/uploads/PTFH-Influenza-Study-Report.pdf

Data on Tetracyclines and Potential in fighting COVID-19

Therapeutic Potential for Tetracyclines in the Treatment of COVID‐19

Another Virology Journal article on Tetracyclines and COVID

The NOSE: data that confirms the NOSE as the focus for COVID Prevention

https://news.mit.edu/2020/researchers-cells-targeted-covid-19-0422/

https://scitechdaily.com/new-evidence-that-cells-in-the-nose-are-key-entry-point-for-sars-cov-2-covid-19/

Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals with COVID-19

Interview Articles:

https://www.bizcatalyst360.com/a-potential-medical-technology-paradigm-shift/

News Radio 102.9 FM Interview with Dr. Brian Huber discussing APT T3X formulation

  1. Independent laboratory tests of the APT™ T3X formulation performed from May 15 -June 25, 2020, Viral Research Services, Ltd.
  2. http://news.mit.edu/2020/researchers-cells-targeted-covid-19-0422
  3. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7263519/